Who owns Adapt Pharma?

On August 28, 2018, Emergent Biosciences Inc. announced the acquisition of Adapt Pharma® for $635 million with the potential for another $100 million in sales-based milestones through 2022. Adapt markets NARCAN® Nasal Spray for the treatment of opioid overdose, for which Opiant Pharmaceuticals, Inc. ( OPNT) receives tiered royalties.

What is Adapt Pharma?

Adapt Pharma was a specialty pharmaceutical company. Adapt Pharma developed and commercialised Narcan Nasal Spray (naloxone) for the reversal of opioid overdose in the U.S. and Canada. The product received approval from the U.S. Food and Drug Administration in November 2015 and Adapt launched the product in February 2016.

Who owns adapthealth stock?

AdaptHealth's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.81%), FMR LLC (7.27%), Truist Financial Corp (2.90%), Rubric Capital Management LP (2.46%), Sumitomo Mitsui Trust Holdings Inc. (2.44%) and State Street Corp (1.97%).